Competitive Environment Table

Compound	Company	Structure	Indication	Stage of development	Mechanism of action
Connexin43	CoDa Therapeutics	Cx43-specific antisense oligodeoxynucleotide	Venous ulcers, DFU	Phase 2	downregulation of Cx43 protein
DSC127	Derma Sciences Inc.	Angiotensin analog	Venous ulcers, pressure ulcers, DFU	Phase 2	Up-regulation of mesenchymal stem cells
Oral BBR-012	Bridge BioResearch Ltd.	Isoniazide	DFU	Phase 2	P450 inhibitor
TRAfermin	Olympus Biotech Corporation	bFGF	DFU	Phase 3	Growth factor
Platelet Rich Fibrin(PRF)	Vivostat	Platelet concentrate in fibrin sealant	DFU	Phase 4	Vascular ingrowth promotion
Controlled nitric oxide releasing patch	Fundación Cardiovascular de Colombia	Topical nitric oxide	DFU	Phase 3	Collagen synthesis, angiogenesis,
rhEGF(recombinant human Epidermal Growth Factor)	Daewoong Pharmaceutical Co.	rhEGF	DFU	Phase 3	Growth factor
KUR-211	Kuros Biosurgery AG	modified variant of platelet-derived growth factor (PDGF)	DFU	Phase 2	Growth factor
Galnobax	Novalead Pharma Private Limited	Esmolol hydrochloride	DFU	Phase 1	short-acting beta-1 adrenergic receptor blocker
LeucoPatch	Reapplix	autologous platelet- rich fibrin	Chronic wounds	Phase 4	Growth factors
HO/03/03	HealOr	PKC-modulating agents	Chronic wounds	Phase 3	PKCa activation and PKCd inhibition
MRE0094	King Pharmaceuticals	Adenosine A2A receptor agonist	DFU	Phase 2	Inflammatory cell mediator
AMD3100	Genzyme	Plerixafor	DFU	Phase 1	Mobilization of endothelial progenitor cells
Woulgan biogel	Biotec Pharmacon ASA	Soluble beta-glucan	DFU	Phase 3	Wound immunomodulating properties